Synthesis, structure and toxicity evaluation of ethanolamine nitro/chloronitrobenzoates: a combined experimental and theoretical study

BACKGROUND

Nitroaromatic and chloronitroaromatic compounds have been a subject of great interest in industry and recently in medical-pharmaceutic field. 2-Chloro-4-nitro/2-chloro-5-nitrobenzoic acids and 4-nitrobenzoic acid are promising new agents for the treatment of main infectious killing diseases in the world: immunodeficiency diseases and tuberculosis.

RESULTS

New ethanolamine nitro/chloronitrobenzoates were synthesized and characterized by X-ray crystallography, UV-vis, FT-IR and elementary analysis techniques. The toxicity of the compounds prepared and correspondent components was evaluated using Hydractinia echinata as test system. A significant lower toxicity was observed for nitro-derivative compared with chloronitro-derivatives and individual components. Crystallographic studies, together with the chemical reactivity and stability profiles resulted from density functional theory and ab initio molecular orbital calculations, explain the particular behavior of ethanolamine 4-nitrobenzoate in biological test.

CONCLUSIONS

The experimental and theoretical data reveal the potential of these compounds to contribute to the design of new active pharmaceutical ingredients with lower toxicity.

Solid-State Versatility of the Molecular Salts/Cocrystals of 2-Chloro-4-nitrobenzoic Acid: A Case Study on Halogen Bonds

2-Chloro-4-nitrobenzoic acid (2c4n) is an antiviral agent used for the treatment of HIV infection and to boost the immune response in immune deficiency diseases. In the present study, a series of eight molecular salts of 2c4n with pyridyl and benzoic acid derivatives have been synthesized by a crystal engineering approach and were characterized structurally by various spectroscopic, thermal, and X-ray diffraction techniques. Crystal structures of all synthesized molecular salts were determined by single-crystal X-ray diffraction techniques. In all synthesized molecular salts, the charge-assisted acid···pyridine/amine heterosynthon was found to be the primary supramolecular synthon. The synthesized salts, namely, 2c4n.g and 2c4n.h salts were found to be isostructural. Further, in the current work, the occurrence of weak halogen bonds in the presence of strong hydrogen bonds in the synthesized and in the reported molecular salts/cocrystals of 2c4n has been investigated. A detailed inspection of the crystal structures of salts/cocrystals of 2c4n was carried out to demonstrate the importance of halogen bonds in these crystal structures. It was found that 4 out of 8 synthesized molecular salts and 12 out of 24 reported molecular adducts of 2c4n were found to exhibit halogen bonds in their crystal structures. A similar kind of conformational change was observed for molecular salts exhibiting halogen bonds in their crystal structures; however, the conformations were found to be slightly different in other molecular salts. It was observed that two-point primary supramolecular synthon and stronger intramolecular Cl···O halogen bonds in the molecular adducts of 2c4n are found to be more susceptible to exhibit halogen bonds in their crystal structures. Halogen bond interactions played a vital role in the crystal stabilization of these molecular adducts.

Pharmaceutical Co-Crystal of Flufenamic Acid: Synthesis and Characterization of Two Novel Drug-Drug Co-Crystal

Two novel pharmaceutical co-crystals of anti-inflammatory drug flufenamic acid (FFA) with 2-chloro-4-nitrobenzoic acid (CNB) and ethenzamide (ETZ) have been synthesized by solvent evaporation method as well as by solvent drop-assisted grinding method. The synthesized co-crystals were characterized thoroughly by various spectroscopic methods and crystal structures were determined by single-crystal x-ray diffraction technique. In FFA-CNB co-crystal, robust supramolecular acid-acid homosynthon was observed. FFA-ETZ co-crystal is formed via robust supramolecular acid-amide heterosynthon. In FTIR spectra, a significant shift in the carbonyl stretching frequency was observed for the co-crystals due to the presence of intermolecular hydrogen bond. ¹H nuclear magnetic resonance study suggests the presence of hydrogen bond in the solution state of FFA-ETZ co-crystal; however, it was absent for FFA-CNB co-crystal. Solubility study in Millipore water revealed that the solubility of FFA is increased by 2-fold when it is in the form of FFA-CNB co-crystal and no increment in the solubility of FFA was observed in FFA-ETZ co-crystal. About 5-fold increment in the solubility of FFA was observed in both the co-crystals in 0.1 N HCl (pH 1) solution. The synthesized co-crystals were found to be non-hygroscopic at ∼75% relative humidity and stable for a period of 6 months at ambient temperature (∼25°C).

Synthesis, characterization, and molecular modeling of a pharmaceutical co-crystal: (2-chloro-4-nitrobenzoic acid):(nicotinamide)

The active pharmaceutical ingredient 2-chloro-4-nitrobenzoic acid (2c4n) is a potentially novel therapy for immunodeficiency diseases as an anti-viral and anti-cancer agent, and exists as a dimorph in the solid state. The Kofler hot stage contact method was employed to investigate the potential of preparing a co-crystal with nicotinamide (nic), a GRAS compound. The 1:1 co-crystal 1 was made using liquid-assisted grinding and solution crystallization experiments. The crystal structure determination of 1 reveals that the two molecules are associated via a carboxylic acid-pyridine hydrogen bond, while the nic forms a centrosymmetric R2(2)(8) dimer to ultimately form a ribbon architecture which is compared to other known co-crystals of nic. The melting point of the co-crystal is higher than the melting points of either of the pure components, indicating that the pharmaceutical co-crystal is thermally more stable than the pure pharmaceutical compound. The relative stability of the interactions in the co-crystal over the pure compounds is further supported by molecular modeling calculations.

Tyrosinase inhibitory effect of benzoic acid derivatives and their structure-activity relationships

A series of benzoic acid derivatives 1-10 have been synthesised by two different methods. Compounds 1-6 were synthesised by a facile procedure for esterification using N,N'-dicyclohexylcarbodiimide (DCC) as a coupling agent, methylene chloride as a solvent system and dimethylaminopyridine (DMAP). While 7-10 were synthesised by converting benzoic acid into benzoyl chloride by treating with thionyl chloride in the presence of benzene and performing a further reaction with amine in dried benzene. The structures of all the synthesised derivatives of benzoic acid (1-10) were assigned on the basis of extensive NMR studies. All of them showed inhibitory potential against tyrosinase. Among them, compound 7 was found to be the most potent (1.09 μM) when compared with the standard tyrosinase inhibitors of kojic acid (16.67 μM) and L-mimosine (3.68 μM). Finally in this paper, we have discussed the structure-activity relationships of the synthesised molecules.

Recent advances in antiviral therapy

In the early 1980s many institutions in Britain were seriously considering whether there was a need for specialist departments of virology. The arrival of HIV changed that perception and since then virology and antiviral chemotherapy have become two very active areas of bio-medical research. Cloning and sequencing have provided tools to identify viral enzymes and have brought the day of the "designer drug" nearer to reality. At the other end of the spectrum of drug discovery, huge numbers of compounds for screening can now be generated by combinatorial chemistry. The impetus to find drugs effective against HIV has also stimulated research into novel treatments for other virus infections including herpesvirus, respiratory infections, and hepatitis B and C viruses. The need to understand the function of the immune system during HIV infection has brought virologists and immunologists together into new partnerships. The huge increase in activity in antiviral research is reflected in the frequency with which these drugs are now being licensed: in 1985 there were two licensed antiviral drugs for systemic use. Since then approximately 20 compounds have been licensed and more are being submitted to the regulatory authorities on a regular basis.